What does Freenome, Inc. do?
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops…
What is Freenome, Inc.'s P/E and P/B ratio?
Freenome, Inc. has a P/E ratio of -6.4 and a P/B ratio of -1.11.
What is Freenome, Inc.'s debt-to-equity ratio?
Freenome, Inc. has a debt-to-equity ratio of -0.25.
How much does Freenome, Inc. owe compared with what it owns?
Freenome, Inc. owes $3.49 for every $1 it owns (balance sheet Dec 2025), which means it owes more than it owns.
What is Freenome, Inc.'s Positivity rank?
Freenome, Inc. is ranked #6,444 of 6,775 companies globally and #3,701 of 4,000 in United States on PositoAI, with a Positivity Score of -19,715.
Does Freenome, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Freenome, Inc. has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 2/10 points): Change of auditor (8-K Item 4.01).
Where can I read the latest news about Freenome, Inc.?
Recent headlines about Freenome, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Freenome, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Freenome, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.